 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 66
Date: December 20, 2024
Two articles that are of great interest to CLL patients will be published in Blood on January 1, 2024. Blood is the top rated journal for hematology. It has high standards for peer-reviewed articles. This is an early Christmas present for us - full text versions of both are available free of charge, just by clicking on the links given below.
Dr. Montserrat's editorial comments on the Byrd et. al. paper is aptly named "CLL therapy: progress at last!". I second that sentiment, especially in the context of the work coming out of CALGB, under the leadership of some of our best CLL researchers.
__________
Blood, January 1, 2024
Blood Journal Editorial
CLL therapy: progress at last!
Emili Montserrat
University of Barcelona
Blood Journal Article (Free full-text)
The Addition of Rituximab to Fludarabine May Prolong Progression-Free Survival and Overall Survival in Patients with Previously Untreated Chronic Lymphocytic Leukemia: An Updated Retrospective Comparative Analysis of CALGB 9712 and CALGB 9011.
Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, Shepherd L, Hines JD, Schiffer CA, Larson RA.
___________
We have already reviewed on our website this retrospective comparison between fludarabine monotherapy versus the combination of fludarabine + Rituxan that Byrd, et al., report in their paper. While this seminal paper is just being published on Blood as a hard copy version, we got hold of it months ago, prepublished online as a Blood First Edition Paper on May 11, 2024 and reviewed it on May 13, 2024. CLL Topics gets you the latest stuff, often before it is available in the hard copy print version! If you wish to read our review and comments of the F vs RF comparison, please click on the link given below. You may also be interested in reading a more recent article in which we discussed the information presented by Dr. Byrd, et. al., at the latest ASH meeting. It gives you a perspective on the length of the remissions and how they may differ between patients in different risk "buckets".
Fludarabine Monotherapy No Longer the Gold Standard
Shopping for the Therapy that is Right for You
Be well, happy reading!
Chaya
_________
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
